Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells

Acta Haematol. 1994;92(4):190-6. doi: 10.1159/000204219.

Abstract

The BCR-ABL fusion gene is directly involved in the pathogenesis of chronic myeloid leukemia (CML). Specific inhibition of the BCR-ABL gene expression with antisense oligodeoxynucleotides has been shown to have profound effects on cell growth in vitro. We examined antisense phosphodiester oligonucleotides (16-mers at a concentration of 60 micrograms/ml) spanning the two possible junction sites K28 (b3a2) and L6 (b2a2) in a clonogenic assay. Single colonies from 9 patients with CML and from patients with normal bone marrow were screened for BCR-ABL expression with a new 'single-tube nested PCR' method. There was a marked reduction in colony number in the CML group and a lesser growth inhibition in the control group. The number and percentage of BCR-ABL-positive colonies, however, was not reduced in the CML group. This indicates a nonspecific growth inhibition only.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Clone Cells
  • DNA Primers / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Hematopoiesis / drug effects
  • Humans
  • In Vitro Techniques
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Molecular Sequence Data
  • Oligonucleotides, Antisense / chemistry*
  • RNA, Neoplasm / genetics
  • Tumor Cells, Cultured

Substances

  • DNA Primers
  • Oligonucleotides, Antisense
  • RNA, Neoplasm
  • Fusion Proteins, bcr-abl